Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
P 4 (2)

Trial Status

Unknown2

Clinical Trials (2)

Showing 2 of 2 trials
NCT05976893Phase 4Unknown

Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

NCT04100434Phase 4Unknown

Effect of Evolocumab Added to Moderate-Intensity Statin Therapy on LDL-C Lowering and Cardiovascular Adverse Events in Patients With Acute Coronary Syndrome

Showing all 2 trials

Research Network

Activity Timeline